Table 1 Baseline clinical, laboratory and echocardiographic parameters of the study groups

Age (years)

59.3 ± 9.9

60.13 ± 10.1

58.42 ± 9.7

Male sex

72 (67.9%)

35 (64.8%)

37 (69.8%)

Height (cm)

163.98 ± 6.5

163.76 ± 6.1

164.21 ± 6.8

Weight (kg)

77.21 ± 9.2

76.72 ± 9.6

77.87 ± 8.6

BMI (Kg/m²)

29.04 ± 6.6

29.33 ± 7.4

28.74 ± 5.6

NYHA

 I–II

64 (59.8%)

35 (64.8%)

29 (54.7%)

 III

25 (23.4%)

11 (20.4%)

14 (26.4%)

 IV

18 (16.8)

8 (14.8%)

10 (18.9%)

Baseline 6MWT

112.88 ± 74.83

104.91 ± 10.3

121.01 ± 10.1

Baseline Serum Cr. (mg/dl)

1.68 ± 0.46

1.72 ± 0.4

1.65 ± 0.4

Baseline eGFR (ml/min/1.73 m²)

49.7 ± 7.63

47.91 ± 7.4

51.55 ± 7.5

Baseline serum K (mEq/L)

4.22 ± 0.59

4.27 ± 0.5

4.16 ± 0.6

Baseline serum albumin

3.4 ± 0.43

3.4 ± 0.5

3.4 ± 0.4

LV Ejection fraction

32.05 ± 2.2

32.31 ± 2.1

31.77 ± 2.4

LV EDD

6.34 ± 0.6

6.33 ± 0.6

6.26 ± 0.7

LV ESD

5.37 ± 0.8

5.27 ± 0.8

5.20 ± 0.9

TR-Vmax (m/s)

2.70 ± 0.7

2.82 ± 0.7

2.52 ± 0.7

Starting diuretic dose†

107 ± 117

100 ± 99

108 ± 104

Starting BB dose ‡

25% ± 22.6

22% ± 20

28% ± 25

Starting MRA dose ‡

61% ± 26

59% ± 22

63% ± 30

Starting RAASi dose ‡

50% [50–50]

50% [50–50]

50% [50–50]